Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
IDeate-Prostate01
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
- NCT06925737 ↗
- Recruiting
- Merck Sharp & Dohme LLC
- Focused
We haven't built an HCP commentary report on IDeate-Prostate01 (ifinatamab deruxtecan, rescue medication and 2 more in Prostate Cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on IDeate-Prostate01 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 6 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3, Open-label Study of Ifinatamab Deruxtecan Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (IDeate-Prostate01)
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Prostate Cancer; Prostatic Neoplasms
- Interventions
- Ifinatamab deruxtecan; Docetaxel; Prednisone; Rescue Medication
- Arms
- I-DXd · Experimental
- Docetaxel · Active comparator
- Enrollment
- 1,440 (estimated)
- Primary outcomes
- Overall Survival (OS)
- Radiographic Progression Free Survival (rPFS)
- Sponsor
- Merck Sharp & Dohme LLC with Daiichi Sankyo
- Start
- May 13, 2025
- Primary completion
- Jun 26, 2028 (estimated)
- Results posted
- No
- Registry record
- NCT06925737 · updated Oct 15, 2026